Veliparib

Overview

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K i s of 5.2 and 2.9 nM, respectively.

Application

Products | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Autophagy | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PARP | Products > Signaling Pathways > Autophagy

Product Information

• Catalog No.: HY-10129
• CAS No.: 912444-00-9
• Molecular Formula: C13H16N4O
• Molecular Weight: 244.29
• Purity: 99.77%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution
• Availability: In-stock

Source

Original product source